Clinical TrialMay 14, 2026, 08:02 AM
Chemomab Nebokitug Data Confirms PSC Potential, Suggests IBD Benefit
AI Summary
Chemomab Therapeutics announced new clinical and translational data for nebokitug, presented at major medical meetings, further confirming its disease-modifying potential in Primary Sclerosing Cholangitis (PSC) and suggesting additional benefits for PSC patients with co-existing Inflammatory Bowel Disease (IBD). The company continues to advance multiple partnering options for nebokitug. For Q1 2026, Chemomab reported a net loss of $1.8 million, an improvement from $3.3 million in Q1 2025, with cash reserves of $8.0 million expected to fund operations through Q1 2027.
Key Highlights
- New clinical data for nebokitug confirms disease-modifying potential in Primary Sclerosing Cholangitis (PSC).
- Data suggests nebokitug's benefit for PSC patients with co-existing Inflammatory Bowel Disease (IBD).
- Chemomab continues to advance multiple partnering options for nebokitug.
- Q1 2026 net loss was $1.8 million, down from $3.3 million in Q1 2025.
- Q1 2026 R&D expenses decreased to $0.9 million from $2.5 million year-over-year.
- Cash, cash equivalents, and short-term deposits totaled $8.0 million as of March 31, 2026.
- Existing liquidity is expected to fund operations through the end of Q1 2027.